



1-800-533-1710

Lipodystrophy Gene Panel

LIPOG

PATIENT NAME ABNORMAL, LIPOG				ORDER NUMBER M229000172
PATIENT ID SA00154616	DATE OF BIRTH 01/01/1980	AGE 42 Y	SEX Female	REQUESTED BY CLIENT CLIENT
COLLECTED 9/28/2022, 11:00 AM	RECEIVED 9/29/2022, 8:29 AM	REPORTED 9/30/2022, 10:51 AM		
The collected, received, and reported dates and times on the report are in the time zone of the performing location. 7028846 MCL RochesterCampus Rochester MN 55901				CLIENT ORDER NUMBER SA00154616 CLIENT MRN SA00154616

TEST DESCRIPTION

Evaluation of 12 genes associated with hereditary lipodystrophy

SPECIMEN

DNA (ul)

RESULT SUMMARY

Pathogenic Variants Detected

RESULT

Gene (Transcript)	Variant	Zygosity	Classification
BSCL2 (NM_032667.6)	c.325dup p.Thr109Asnfs*5 (p.T109Nfs*5) Chr11(GRCh37):g.62462153dup	Homozygous	Pathogenic

The following homozygous PATHOGENIC variant was detected: BSCL2 (NM_032667.6), Chr11 (GRCh37):g.62462153dup, c.325dup, p.Thr109Asnfs*5 (p.T109Nfs*5)

No additional reportable pathogenic variants, likely pathogenic variants, or variants of uncertain significance were detected within all other tested genes. See the Genes Analyzed section for a complete list of genes evaluated by the assay.

INTERPRETATION

BSCL2: c.325dup (p.Thr109Asnfs*5): The homozygous c.325dup (p.Thr109Asnfs*5) variant in the BSCL2 gene (MIM: 606158) is classified as pathogenic. The BSCL2 gene encodes seipin, a protein important for lipid droplet formation within the endoplasmic reticulum. Pathogenic variants in this gene are associated with autosomal recessive Berardinelli-Seip Congenital Lipodystrophy (BSCL), a form of congenital generalized lipodystrophy. This variant has been reported to occur in the homozygous state in many affected individuals of Portuguese descent and is considered a Brazilian/Portuguese founder variant (1-6). Other truncating variants in the BSCL2 gene have been reported in association with Berardinelli-Seip congenital lipodystrophy. Finally, functional studies suggest that this variant may impact protein function (7-8), however additional studies are needed to confirm the biological impact of this variant. Taken together, this result is supportive of a diagnosis of Berardinelli-Seip congenital lipodystrophy (BSCL) for this individual. Clinical correlation is recommended.

This result should be interpreted in the context of clinical findings, family history, and other laboratory testing.

Consultation with a genetics professional is recommended for interpretation of this result and to determine whether reproductive risk assessment and familial testing may be of benefit to this family. Genetic testing for family members is available by ordering FMTT / Familial Mutation, Targeted Testing for the specific variant(s) detected. Please contact the laboratory at 1-800-533-1710 or the online test catalog at www.mayocliniclabs.com for information about FMTT.



1-800-533-1710

Lipodystrophy Gene Panel

LIPOG

PATIENT NAME ABNORMAL, LIPOG				ORDER NUMBER M229000172
PATIENT ID SA00154616	DATE OF BIRTH 01/01/1980	AGE 42 Y	SEX Female	REQUESTED BY CLIENT CLIENT
COLLECTED 9/28/2022, 11:00 AM	RECEIVED 9/29/2022, 8:29 AM	REPORTED 9/30/2022, 10:51 AM		
The collected, received, and reported dates and times on the report are in the time zone of the performing location. 7028846 MCL RochesterCampus Rochester MN 55901				CLIENT ORDER NUMBER SA00154616 CLIENT MRN SA00154616

REFERENCES:

1. Magré J, Delépine M, Khallouf E, et al. Identification of the gene altered in Berardinelli-Seip congenital lipodystrophy on chromosome 11q13. Nat Genet. 2001;28(4):365-370. doi:10.1038/ng585 (PMID: 11479539)
2. Bhayana S, Siu VM, Joubert GI, Clarson CL, Cao H, Hegele RA. Cardiomyopathy in congenital complete lipodystrophy. Clin Genet. 2002;61(4):283-287. doi:10.1034/j.1399-0004.2002.610407.x (PMID: 12030893)
3. Gomes KB, Pardini VC, Ferreira AC, Fonseca CG, Fernandes AP. Founder effect of the 669insA mutation in BSCL2 gene causing Berardinelli-Seip congenital lipodystrophy in a cluster from Brazil. Ann Hum Genet. 2007;71(Pt 6):729-734. doi:10.1111/j.1469-1809.2007.00369.x (PMID: 17535271)
4. Lima JG, Nobrega LHC, Lima NN, et al. Causes of death in patients with Berardinelli-Seip congenital generalized lipodystrophy. PLoS One. 2018;13(6):e0199052. Published 2018 Jun 8. doi:10.1371/journal.pone.0199052 (PMID: 29883474)
5. Lima GEDCP, Fernandes VO, Montenegro APDR, et al. Aggressive papillary thyroid carcinoma in a child with type 2 congenital generalized lipodystrophy. Arch Endocrinol Metab. 2019;63(1):79-83. doi:10.20945/2359-3997000000096 (PMID: 30864635)
6. Costa-Riquetto AD, Santana LS, Caetano LA, et al. Targeted massively parallel sequencing for congenital generalized lipodystrophy. Arch Endocrinol Metab. 2021;64(5):559-566. doi:10.20945/2359-3997000000278 (PMID: 34033296)
7. Wang H, Becuwe M, Housden BE, et al. Seipin is required for converting nascent to mature lipid droplets. Elife. 2016;5:e16582. Published 2016 Aug 26. doi:10.7554/eLife.16582 (PMID: 27564575)
8. Craveiro Sarmiento AS, Gomes Lima J, de Souza Timoteo AR, et al. Changes in redox and endoplasmic reticulum homeostasis are related to congenital generalized lipodystrophy type 2. Biochim Biophys Acta Mol Cell Biol Lipids. 2020;1865(4):158610. doi:10.1016/j.bbalip.2020.158610 (PMID: 31917334)

METHOD

Next generation sequencing (NGS) and/or Sanger sequencing was performed to test for the presence of variants in coding regions and intron/exon boundaries of the genes analyzed, as well as some other regions that have known pathogenic variants. The human genome reference GRCh37/hg19 build was used for sequence read alignment. At least 99% of the bases are covered at a read depth over 30X. Sensitivity is estimated at above 99% for single nucleotide variants, above 94% for indels less than 40 base pairs (bp), above 95% for deletions up to 75 bp and insertions up to 47 bp. NGS, and/or a polymerase chain reaction (PCR)-based quantitative method was performed to test for the presence of deletions and duplications in the genes analyzed. See the Genes Analyzed field for a list of genes tested.

There may be regions of genes that cannot be effectively evaluated for sequencing or deletion and duplication analysis as a result of technical limitations of the assay, including regions of homology, high GC content, and repetitive sequences. Confirmation of select reportable variants was performed by alternate methodologies based on internal laboratory criteria. See www.mayocliniclabs.com (TEST ID LIPOG) for details regarding genes with regions not routinely covered.

GENES ANALYZED

AGPAT2, BSCL2, CAV1, CAVIN1, FBN1, KCNJ6, LIPE, LMNA, PIK3R1, PLIN1, PPARG, ZMPSTE24

DISCLAIMER

Clinical Correlations

An online research opportunity called GenomeConnect (genomeconnect.org), a project of ClinGen, is available for the recipient of this genetic test. This patient registry collects de-identified genetic and health information to advance the

PATIENT NAME ABNORMAL, LIPOG

22-39490



1-800-533-1710

Lipodystrophy Gene Panel

LIPOG

PATIENT NAME ABNORMAL, LIPOG				ORDER NUMBER M229000172
PATIENT ID SA00154616	DATE OF BIRTH 01/01/1980	AGE 42 Y	SEX Female	REQUESTED BY CLIENT CLIENT
COLLECTED 9/28/2022, 11:00 AM	RECEIVED 9/29/2022, 8:29 AM	REPORTED 9/30/2022, 10:51 AM		
The collected, received, and reported dates and times on the report are in the time zone of the performing location.				CLIENT ORDER NUMBER SA00154616
7028846 MCL RochesterCampus Rochester MN 55901				CLIENT MRN SA00154616

knowledge of genetic variants. Mayo Clinic is a collaborator of ClinGen. This may not be applicable for all tests.

If testing was performed because of a clinically significant family history it is often useful to first test an affected family member. Detection of a reportable variant(s) in an affected family member would allow for more informative testing of at risk individuals.

To discuss the availability of further testing options or for assistance in the interpretation of these results, Mayo Clinic Laboratory genetic counselors can be contacted at 1-800-533-1710.

Technical Limitations

Next generation sequencing may not detect all types of genomic variants. In rare cases, false negative or false positive results may occur. The depth of coverage may be variable for some target regions, but assay performance below the minimum acceptable criteria or for failed regions will be noted. Given these limitations, negative results do not rule out the diagnosis of a genetic disorder. If a specific clinical disorder is suspected, evaluation by alternative methods can be considered.

There may be regions of genes that cannot be effectively evaluated for sequencing or deletion and duplication analysis as a result of technical limitations of the assay, including regions of homology, high GC content, and repetitive sequences. Confirmation of select reportable variants was performed by alternate methodologies based on internal laboratory criteria.

Additionally, low level mosaic variants may not be detected.

This test is not designed to differentiate between somatic and germline variants. If there is a possibility that any detected variant is somatic, additional testing may be necessary to clarify the significance of results.

Genes may be added or removed based on updated clinical relevance. Please refer to the Targeted Genes and Methodology Details for the Lipodystrophy Gene Panel in the Special Instructions section of the Test Catalog for the most up to date list of genes included in this test.

Reclassification of Variants Policy

See www.mayocliniclabs.com (TEST ID LIPOG) for information regarding the laboratory's policy for reclassification of variants.

Variant Evaluation

Variant curation is performed using published ACMG-AMP recommendations as a guideline. Other gene-specific guidelines may also be considered. Variants classified as benign or likely benign are not reported.

Results from in silico evaluation tools may change over time and should be interpreted with caution and professional clinical judgment.

TEST CLASSIFICATION

PATIENT NAME	ABNORMAL, LIPOG	22-39490
--------------	-----------------	----------



1-800-533-1710

Lipodystrophy Gene Panel

LIPOG

PATIENT NAME ABNORMAL, LIPOG				ORDER NUMBER M229000172
PATIENT ID SA00154616	DATE OF BIRTH 01/01/1980	AGE 42 Y	SEX Female	REQUESTED BY CLIENT CLIENT
COLLECTED 9/28/2022, 11:00 AM	RECEIVED 9/29/2022, 8:29 AM	REPORTED 9/30/2022, 10:51 AM		
The collected, received, and reported dates and times on the report are in the time zone of the performing location.				CLIENT ORDER NUMBER SA00154616
7028846 MCL RochesterCampus Rochester MN 55901				CLIENT MRN SA00154616

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

RELEASED BY

Linnea M. Baudhuin, Ph.D.

Code : MCR Laboratory : Mayo Clinic Laboratories - Rochester Main Campus
Lab Director : WILLIAM G MORICE, II MD, PhD CLIA Certificate : 24D0404292

Address : 200 FIRST STREET SW
ROCHESTER MN 55905